Literature DB >> 16286491

Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease.

I Gemmell1, R F Heller, P McElduff, K Payne, G Butler, R Edwards, M Roland, P Durrington.   

Abstract

STUDY
OBJECTIVE: To assess the potential number of lives saved associated with the full implementation of aspects of the National Service Framework (NSF) for coronary heart disease (CHD) in England using recently developed population impact measures.
DESIGN: Modelling study.
SETTING: Primary care. DATA SOURCES: Published data on prevalence of acute myocardial infarction and heart failure, baseline risk of mortality, the relative risk reduction associated with different interventions and the proportion treated, eligible for treatment and adhering to each intervention. MAIN
RESULTS: Adopting the NSF recommendations for pharmacological interventions would prevent an extra 1027 (95% CI 418 to 1994) deaths in post-acute myocardial infarction (AMI) patients and an extra 37 899 (95% CI 25 690 to 52 503) deaths in heart failure patients in the first year after diagnosis. Lifestyle based interventions would prevent an extra 848 (95% CI 71 to 1 614) deaths in post-AMI patients and an extra 7249 (95% CI 995 to 16 696) deaths in heart failure patients.
CONCLUSIONS: Moving from current to "best" practice as recommended in the NSF will have a much greater impact on one year mortality rates among heart failure patients compared with post-AMI patients. Meeting pharmacological based recommendations for heart failure patients will prevent more deaths than meeting lifestyle based recommendations. Population impact numbers can help communicate the impact on a population of the implementation of guidelines and, when created using local data, could help policy makers assess the local impact of implementing a range of health care targets.

Entities:  

Mesh:

Year:  2005        PMID: 16286491      PMCID: PMC1732977          DOI: 10.1136/jech.2005.035717

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  50 in total

Review 1.  Enhancing drug compliance in lipid-lowering treatment.

Authors:  J H LaRosa; J C LaRosa
Journal:  Arch Fam Med       Date:  2000 Nov-Dec

2.  Disease impact number and population impact number: population perspectives to measures of risk and benefit.

Authors:  R F Heller; A J Dobson
Journal:  BMJ       Date:  2000-10-14

3.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Authors:  M D Flather; S Yusuf; L Køber; M Pfeffer; A Hall; G Murray; C Torp-Pedersen; S Ball; J Pogue; L Moyé; E Braunwald
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

4.  Secondary prevention of coronary heart disease in primary care: a healthy heart initiative.

Authors:  D E Flanagan; P Cox; D Paine; J Davies; M Armitage
Journal:  QJM       Date:  1999-05

5.  Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure.

Authors:  C M Roe; B R Motheral; F Teitelbaum; M W Rich
Journal:  Am Heart J       Date:  1999-11       Impact factor: 4.749

6.  Trends in case-fatality in 117 718 patients admitted with acute myocardial infarction in Scotland.

Authors:  S Capewell; B M Livingston; K MacIntyre; J W Chalmers; J Boyd; A Finlayson; A Redpath; J P Pell; C J Evans; J J McMurray
Journal:  Eur Heart J       Date:  2000-11       Impact factor: 29.983

7.  Sex inequalities in ischaemic heart disease in general practice: cross sectional survey.

Authors:  J Hippisley-Cox; M Pringle; N Crown; A Meal; A Wynn
Journal:  BMJ       Date:  2001-04-07

8.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.

Authors: 
Journal:  Eur Heart J       Date:  2001-04       Impact factor: 29.983

9.  Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995.

Authors:  K MacIntyre; S Capewell; S Stewart; J W Chalmers; J Boyd; A Finlayson; A Redpath; J P Pell; J J McMurray
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

10.  Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group.

Authors:  R Latini; G Tognoni; A P Maggioni; C Baigent; E Braunwald; Z M Chen; R Collins; M Flather; M G Franzosi; J Kjekshus; L Køber; L S Liu; R Peto; M Pfeffer; F Pizzetti; E Santoro; P Sleight; K Swedberg; L Tavazzi; W Wang; S Yusuf
Journal:  J Am Coll Cardiol       Date:  2000-06       Impact factor: 24.094

View more
  4 in total

1.  The population effect of crime and neighbourhood on physical activity: an analysis of 15,461 adults.

Authors:  Roger A Harrison; Islay Gemmell; Richard F Heller
Journal:  J Epidemiol Community Health       Date:  2007-01       Impact factor: 3.710

2.  Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies.

Authors:  I Gemmell; R F Heller; K Payne; R Edwards; M Roland; P Durrington
Journal:  Qual Saf Health Care       Date:  2006-10

3.  Estimating the potential population impact of stepwise screening strategies for identifying and treating individuals at high risk of Type 2 diabetes: a modelling study.

Authors:  P Chamnan; R K Simmons; K T Khaw; N J Wareham; S J Griffin
Journal:  Diabet Med       Date:  2012-07       Impact factor: 4.359

4.  Use of medicines recommended for secondary prevention of acute coronary syndrome.

Authors:  Mari Ângela Gaedke; Juvenal Soares Dias da Costa; Euler Roberto Fernandes Manenti; Ruth Liane Henn; Vera Maria Vieira Paniz; Marcelo Felipe Nunes; Monique Adriane da Motta; Maria Teresa Anselmo Olinto
Journal:  Rev Saude Publica       Date:  2016-01-15       Impact factor: 2.106

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.